<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00799643</url>
  </required_header>
  <id_info>
    <org_study_id>CHS 06-20-2</org_study_id>
    <secondary_id>U01DK074556</secondary_id>
    <nct_id>NCT00799643</nct_id>
  </id_info>
  <brief_title>Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II</brief_title>
  <acronym>TINSALT2D-II</acronym>
  <official_title>Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Growing evidence over recent years supports a potential role for low grade chronic
      inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we
      will determine whether salsalate, a member of the commonly used Non-Steroidal
      Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2
      diabetes. The study will determine whether salicylates represent a new pharmacological option
      for diabetes management. The study is conducted in two stages. Enrollment in the first stage
      is complete. The primary objective of the first stage was to select a dose of salsalate that
      is both well-tolerated and demonstrates a trend toward improvement in glycemic control. The
      primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood
      sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes
      (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and
      cardiac risk.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.</measure>
    <time_frame>48 weeks from baseline</time_frame>
    <description>HbA1c (%, percentage of HbA1c) change from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Glucose Over Time.</measure>
    <time_frame>48 weeks from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates for Reduction in Fasting Glucose of ≥20 mg/dl, a Reduction in HbA1c of ≥0.5%, and a Reduction in HbA1c of ≥0.8%</measure>
    <time_frame>24 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lipids (Low-density Lipoprotein Cholesterol [LDL-C], Non-high-density Lipoprotein Cholesterol [Non-HDL-C], Triglycerides [TG], Total Cholesterol [TC], High-density Lipoprotein Cholesterol [HDL C], TC/HDL-C Ratio, and LDL-C/HDL-C Ratio)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in WBC and Differential, High-sensitivity C Reactive Protein (hsCRP), Other Inflammatory Markers</measure>
    <time_frame>24 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates for Exceeding Hyperglycemic Targets Between Active and Placebo Treated Groups; Need for Rescue Therapy; Need for Discontinuation of Study Medication</measure>
    <time_frame>24 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates in Patients Initially Treated With Lifestyle Modification, Insulin Secretagogue, Metformin or Combination Therapy</measure>
    <time_frame>24 and 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">638</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salsalate, 3.5 g/d orally, divided dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Salsalate Placebo, orally, divided dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salsalate</intervention_name>
    <description>Salsalate 3.5 g/d orally, divided dosing</description>
    <arm_group_label>1</arm_group_label>
    <other_name>disalsid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salsalate Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes on diet and exercise therapy or monotherapy with metformin, insulin
             secretagogue (including SFU, non-SFU, and dipeptidyl peptidase IV (DPP-4) inhibitors),
             alpha-glucosidase inhibitors, or bile acid sequestrants (dosed once per day such that
             study drug can be administered ≥ 4 hours prior to sequestrant); or a combination of up
             to two of these at maximal dose. Dosing must be stable for 8 weeks prior to screening.
             Participant must have been diagnosed with T2D at least 8 weeks before screening.

          2. FPG ≤ 225 mg/dL and HbA1c≥7% and ≤ 9.5% at screening.

          3. Age ≥18 and &lt;75

          4. Women of childbearing potential agree to use an appropriate contraceptive method
             (hormonal, IUD, or diaphragm)

        Exclusion Criteria:

          1. No prior participation in Stage I of TINSAL-T2D ; exception: a participant who failed
             screening for HbA1c in Stage I will be allowed to re-screen for Stage II.

          2. Type 1 diabetes and/or history of ketoacidosis determined by medical history

          3. History of severe diabetic neuropathy including autonomic neuropathy, gastroparesis or
             lower limb ulceration or amputation

          4. History of long-term therapy with insulin (&gt;30 days) within the last year

          5. Therapy with rosiglitazone (Avandia) or pioglitazone (Actos), alone or in combination
             in the previous 6 months; or exendin-4 (Byetta), alone or in combination in the
             previous 3 months

          6. Pregnancy or lactation

          7. Patients requiring oral corticosteroids within 3 months or recurrent continuous oral
             corticosteroid treatment (more than 2 weeks)

          8. Use of weight loss drugs [e.g., Xenical (orlistat), Meridia (sibutramine), Acutrim
             (phenylpropanol-amine), or similar over-the-counter medications] within 3 months of
             screening or intentional weight loss of ≥ 10 lbs in the previous 6 months

          9. Surgery within 30 days prior to screening

         10. Serum creatinine &gt;1.4 for women and &gt;1.5 for men or eGFR &lt;60 [possible chronic kidney
             disease stage 3 or greater calculated using the Modification of Diet in Renal Disease
             (MDRD) equation

         11. History of chronic liver disease including hepatitis B or C

         12. History of peptic ulcer or endoscopy demonstrated gastritis

         13. History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV)

         14. History of malignancy, except participants who have been disease-free for greater than
             10 years, or whose only malignancy has been basal or squamous cell skin carcinoma

         15. New York Heart Association Class III or IV cardiac status or hospitalization for
             congestive heart failure

         16. History of unstable angina, myocardial infarction, cerebrovascular accident, transient
             ischemic attack or any revascularization within 6 months

         17. Uncontrolled hypertension (defined as systolic blood pressure &gt;150 mmHg or diastolic
             blood pressure &gt;95 mmHg on three or more assessments on more than one day). If on
             blood pressure medications, dosing should be stable for 2 weeks prior to
             randomization.

         18. History of drug or alcohol abuse, or current weekly alcohol consumption &gt;10 units/week
             (1 unit = 1 beer, 1 glass of wine, 1 mixed DCCktail containing 1 ounce of alcohol)

         19. Hemoglobin &lt;12 g/dL (males), &lt;10 g/dL (females) at screening*

         20. Platelets &lt;100,000 cu mm at screening

         21. AST (SGOT) &gt;2.50 x ULN or ALT (SGPT) &gt;2.50 x ULN at screening

         22. Total Bilirubin &gt;1.50 x ULN at screening

         23. Triglycerides (TG) &gt;500 mg/dL at screening

         24. Poor mental function or any other reason to expect patient difficulty in complying
             with the requirements of the study

         25. Previous allergy to aspirin

         26. Chronic or continuous use (daily for more than 7 days) of nonsteroidal
             anti-inflammatory drugs within the preceding 2 months

         27. Use of warfarin (Coumadin), clopidogrel (Plavix), dipyridamole (Persantine), heparin
             or other anticoagulants

         28. Use of probenecid (Benemid, probalan), sulfinpyrazone (Anturane) or other uricosuric
             agents

         29. Macroalbuminuria, defined as spot urine protein &gt;300 mcg/mg Cr at screening

         30. Pre-existing chronic tinnitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven E. Shoelson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allison B. Goldfine, MD</last_name>
    <role>Study Director</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vivian Fonseca, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen Jablonski, PhD</last_name>
    <role>Study Director</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myrlene Staten, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Medical Group</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Research Institute</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Rudo, Westminster, MD</name>
      <address>
        <city>Westminster</city>
        <state>Maryland</state>
        <zip>21157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Diabetes and Endocrine Associates</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lang Medical Center</name>
      <address>
        <city>Queens</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina's Health Care</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 Jul;116(7):1793-801. Review. Erratum in: J Clin Invest. 2006 Aug;116(8):2308.</citation>
    <PMID>16823477</PMID>
  </reference>
  <reference>
    <citation>Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008 Feb;31(2):289-94. Epub 2007 Oct 24.</citation>
    <PMID>17959861</PMID>
  </reference>
  <reference>
    <citation>Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008 May;1(1):36-43. doi: 10.1111/j.1752-8062.2008.00026.x.</citation>
    <PMID>19337387</PMID>
  </reference>
  <reference>
    <citation>Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010 Mar 16;152(6):346-57. doi: 10.7326/0003-4819-152-6-201003160-00004.</citation>
    <PMID>20231565</PMID>
  </reference>
  <results_reference>
    <citation>Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013 Jul 2;159(1):1-12. doi: 10.7326/0003-4819-159-1-201307020-00003.</citation>
    <PMID>23817699</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2008</study_first_submitted>
  <study_first_submitted_qc>November 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2008</study_first_posted>
  <results_first_submitted>September 13, 2013</results_first_submitted>
  <results_first_submitted_qc>September 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2013</results_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus (T2D)</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Obesity</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Salicylates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylsalicylic acid</mesh_term>
    <mesh_term>Sodium Salicylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The Enrollment number in the protocol section (638) is higher than the number of participants Started in the Participant Flow module (286) due to screen failures and drop out prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo for salsalate, orally, divided dosing</description>
        </group>
        <group group_id="P2">
          <title>Salsalate</title>
          <description>Salsalate, 3.5 g/d orally,divided dosing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo for salsalate, orally, divided dosing</description>
        </group>
        <group group_id="B2">
          <title>Salsalate</title>
          <description>Salsalate, 3.5 g/d orally, divided dosing</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="146"/>
            <count group_id="B3" value="286"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.8" spread="10"/>
                    <measurement group_id="B2" value="55.8" spread="9.2"/>
                    <measurement group_id="B3" value="55.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.</title>
        <description>HbA1c (%, percentage of HbA1c) change from baseline.</description>
        <time_frame>48 weeks from baseline</time_frame>
        <population>Participants with complete data at both Baseline and 48 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for salsalate, orally, divided dosing</description>
          </group>
          <group group_id="O2">
            <title>Salsalate</title>
            <description>Salsalate, 3.5 g/d orally, divided dosing</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.</title>
          <description>HbA1c (%, percentage of HbA1c) change from baseline.</description>
          <population>Participants with complete data at both Baseline and 48 weeks</population>
          <units>HbA1c units are %</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.07" upper_limit="0.15"/>
                    <measurement group_id="O2" value="-0.33" lower_limit="-0.44" upper_limit="-0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Glucose Over Time.</title>
        <time_frame>48 weeks from baseline</time_frame>
        <population>Participants with complete data at both Baseline and 48 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for salsalate, orally, divided dosing</description>
          </group>
          <group group_id="O2">
            <title>Salsalate</title>
            <description>Salsalate, 3.5 g/d orally,divided dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Glucose Over Time.</title>
          <population>Participants with complete data at both Baseline and 48 weeks</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-1.9" upper_limit="5.9"/>
                    <measurement group_id="O2" value="-13.1" lower_limit="-16.9" upper_limit="-9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rates for Reduction in Fasting Glucose of ≥20 mg/dl, a Reduction in HbA1c of ≥0.5%, and a Reduction in HbA1c of ≥0.8%</title>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lipids (Low-density Lipoprotein Cholesterol [LDL-C], Non-high-density Lipoprotein Cholesterol [Non-HDL-C], Triglycerides [TG], Total Cholesterol [TC], High-density Lipoprotein Cholesterol [HDL C], TC/HDL-C Ratio, and LDL-C/HDL-C Ratio)</title>
        <time_frame>48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in WBC and Differential, High-sensitivity C Reactive Protein (hsCRP), Other Inflammatory Markers</title>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rates for Exceeding Hyperglycemic Targets Between Active and Placebo Treated Groups; Need for Rescue Therapy; Need for Discontinuation of Study Medication</title>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rates in Patients Initially Treated With Lifestyle Modification, Insulin Secretagogue, Metformin or Combination Therapy</title>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo for salsalate, orally, divided dosing</description>
        </group>
        <group group_id="E2">
          <title>Salsalate</title>
          <description>Salsalate, 3.5 g/d orally,divided dosing</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Lymphoid Leukemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallstones/Cholycystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Degenerative Joint Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Traumatic Fracture or Joint Diastasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Cervical Disectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria/Bladder Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Benign Prostate Hypertrophy/TURP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Kidney Stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Reactive Airway Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Vascular Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizzy</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Weakness or Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Stiffness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allison B.Goldfine</name_or_title>
      <organization>Joslin Diabetes Center</organization>
      <phone>617-309-2400</phone>
      <email>allison.goldfine@joslin.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

